Awesome. Thank you very much.
I could go on all day with something like this.
Professor Herder mentioned something about a national decision-maker. This is one of the things that I struggle with, and I know about all of the great work that you've done, Dr. Wong-Rieger, in the past on rare disorders, which I thank you for.
My colleague has mentioned private insurance versus the public purse, and we've had different advocates here in that regard. Some do want that public system focused on. I know that Dr. McCabe was with the National Health Service, and it would be great in Canada. I've always thought that we just needed one decision-maker to work that out because all these silos are a bit of a challenge.
My concern is, who decides, and what do they base that on? I've had constituents in the past... I remember when Remicade came out, which I think might have been the drug you were talking about. Some of these make a huge difference. Sometimes a private insurance company may make that more available, and it can be a life changing thing, whereas the national system may take a lot longer to get that.
How do you see a balance on this system, and who makes that decision?